Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Preferred Stock Liabilities (2023 - 2024)

Historic Preferred Stock Liabilities for Beta Bionics (BBNX) over the last 2 years, with Q4 2024 value amounting to $321.4 million.

  • Beta Bionics' Preferred Stock Liabilities rose 2279.6% to $321.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $321.4 million, marking a year-over-year increase of 2279.6%. This contributed to the annual value of $321.4 million for FY2024, which is 2279.6% up from last year.
  • Beta Bionics' Preferred Stock Liabilities amounted to $321.4 million in Q4 2024, which was up 2279.6% from $261.7 million recorded in Q3 2024.
  • Over the past 5 years, Beta Bionics' Preferred Stock Liabilities peaked at $321.4 million during Q4 2024, and registered a low of $261.7 million during Q4 2023.